This invention describes a method that efficiently stops the growth of cancer cells or over-proliferative cells without causing adverse cytotoxic effects on the body’s healthy organs and tissues. This technology focuses on the IMPA1/RAGE complex and its ability to control cell proliferation.
Proliferative disorders include a wide variety of diseases, such as cancer, atherosclerosis, rheumatoid arthritis, psoriasis, idiopathic pulmonary fibrosis, scleroderma, and more. Hundreds of thousands of individuals suffer from these disorders. Cell proliferation can be triggered by the binding between the Inositol monophosphate 1 (IMPA1) enzyme the receptor for advanced glycation endproducts (RAGE). The inventors here have identified peptide inhibitors designed to block the interaction between IMPA1 and RAGE and inhibit the downstream proliferative signaling. To note, these peptide inhibitors are a unique therapeutic strategy that can selectively arrest the growth of over-proliferative cells in patients with cancers and other proliferative disorders without producing any toxicity on the healthy cell population.
- Used in a clinical setting to treat proliferative diseases like:
- Pulmonary hypertension
- Diabetic retinopathy
- Liver cirrhosis
- Pulmonary fibrosis
- Protects healthy cells
- Inhibits further cell damage done by diseases
- Widely applicable to many different disorders
TTO Home Page: https://arizona.technologypublisher.com
Name: Mitch Graffeo
Title: Sr. Licensing Manager - COM-T